3rd Apr 2008 08:35
Oxford Biomedica PLC03 April 2008 For Immediate Release 3 April 2008 Oxford BioMedica plc ("Oxford BioMedica" or the "Company") Annual Information Update for the Twelve Months to 2 April 2008 Oxford BioMedica is providing an annual information update pursuant toProspectus Rule 5.2 made by the Financial Services Authority. 1. Announcements made via a Regulatory Information Service Date Announcement 3 April 2007 Directors' interests in shares and share options7 April 2007 Holding(s) in Company16 April 2007 Annual information update27 April 2007 Directors' interests in shares and share options30 April 2007 Holding(s) in Company30 April 2007 Total voting rights update1 May 2007 RetinoStat and StarGen preclinical data presented3 May 2007 AGM statement7 May 2007 Avian Transgenic project update17 May 2007 Hi-8 MEL clinical data presentation17 May 2007 Blocklisting interim review22 May 2007 Holding(s) in Company24 May 2007 Corporate presentation at FBR Growth conference29 May 2007 Notice of TroVax clinical data presentation31 May 2007 Total voting rights update3 June 2007 TroVax clinical data presentation18 June 2007 Corporate presentation at Piper Jaffrey healthcare conference22 June 2007 TechMark Mediscience breakthrough of the year award22 June 2007 Viragen transgenic collaboration terminated28 June 2007 Holding(s) in Company29 June 2007 Total voting rights update2 July 2007 LentiVector licence with major biotechnology company6 July 2007 Licence for anti-cancer genes and share subscription25 July 2007 TroVax Phase III DSMB positive review31 July 2007 Total voting rights update2 August 2007 Publication of TroVax phase II clinical data2 August 2007 Holding(s) in Company3 August 2007 Holding(s) in Company29 August 2007 Holding(s) in Company30 August 2007 Holding(s) in Company31 August 2007 Total voting rights update11 September 2007 TroVax collaboration milestone11 September 2007 Interim results28 September 2007 Holding(s) in Company22 October 2007 Directors' interests in shares and share options25 October 1007 Business update and comment on share price movement25 October 2007 Directors' interests in shares and share options26 October 2007 Litigation against Open Biosystems - favourable ruling9 November 2007 Change of broker - appointment of JP Morgan Cazenove16 November 2007 Blocklisting interim review29 November 2007 TechMark achievement of the year award5 December 2007 Scrip licensing deal of the year award6 December 2007 Holding(s) in Company10 December 2007 TroVax Phase III DSMB positive review13 December 2007 ProSavin initiation of Phase I/II clinical trial18 December 2007 Holding(s) in Company7 January 2008 Licence for RNAi technology and share subscription18 January 2008 Holding(s) in Company22 January 2008 Milestone in collaboration with Molmed S.p.A22 January 2008 Holding(s) in Company29 January 2008 Holding(s) in Company31 January 2008 Total voting rights update1 February 2008 Holding(s) in Company7 February 2008 Notice of results13 February 2008 Holding(s) in Company14 February 2008 Holding(s) in Company19 February 2008 Holding(s) in Company20 February 2008 TroVax Phase III DSMB positive review and collaboration milestone29 February 2008 Total voting rights update10 March 2008 TroVax Phase III clinical trial completion of recruitment10 March 2008 Appointment of non-executive director10 March 2008 Preliminary results for 200713 March 2008 Directors' interests in shares and share options17 March 2008 Corporate presentation at Cowen & Co. healthcare conference18 March 2008 Holding(s) in Company25 March 2008 TroVax clinical data presentation31 March 2008 Total voting rights update1 April 2008 Holding(s) in Company2 April 2008 Annual information update Details of all regulatory announcements for Oxford BioMedica can be found on theLondon Stock Exchange website at www.londonstockexchange.com and on the OxfordBioMedica website at http://www.oxfordbiomedica.co.uk 2. Documents filed with Companies House Date Document Type Description 26 September 88(2) Return of Allotment of Allotment 122,815 1p Ord. 2007 shares 26 September 88(2) Return of Allotment of Allotment 414,162 1p Ord. 2007 shares 26 September 88(2) Return of Allotment of Allotment 394,617 1p Ord. 2007 shares 26 September 88(2) Return of Allotment of Allotment 144,631 1p Ord. 2007 shares 26 September 363s Annual Return 2007 14 March 2008 288a Appointment of director Dr Alex Lewis 2 April 2008 88(2) Return of Allotment of Allotment 2,418,473 1p shares Ord. Copies of documents filed at Companies House can be obtained from CompaniesHouse, Crown Way, Cardiff CF14 3UZ or through Companies House Direct atwww.direct.companieshouse.gov.uk 3. Documents published or sent to shareholders or filed with the UKLA Viewing Facility Date Description 21 September 2007 Interim Report for 6 months to 30 June 2007 Copies of all the above documents may be obtained from the Company Secretary atthe Company's Registered Office: This annual information update is filed pursuant to Prospectus Rule 5.2 made bythe Financial Services Authority and not for any other purpose and by filingthis annual information update neither the Company, nor any other person, takesany responsibility for, or makes any representation, express or implied, as tothe accuracy or completeness of, the information contained or referred to belowherein. The information referred to below is not necessarily up to date as atthe date of this annual information update and the Company does not undertakeany obligation to update any such information in the future. Furthermore, suchinformation may have been prepared in accordance with the laws or regulations ofa particular jurisdiction and may not comply with or meet the relevant standardsof disclosure in any other jurisdiction. Neither this annual information update,nor the information referred to below constitutes, by virtue of thiscommunication, an offer of any securities addressed to any person and should notbe relied on by any person. Oxford BioMedica plc Medawar Centre Robert Robinson Avenue The Oxford Science Park Oxford OX4 4GA 2 April 2008 For further information, please contact: For further information, please contact: Oxford BioMedica plc: Professor Alan Kingsman, Chief Executive Tel: +44 (0)1865 783 000 JPMorgan Cazenove Limited: James Mitford/ Gina Gibson Tel: +44 (0)20 7588 2828 City/Financial Enquiries: Lisa Baderoon/ Mark Court/ Mary-Jane Johnson Tel: +44 (0)20 7466 5000 Buchanan Communications Scientific/Trade Press Enquiries: Gemma Price/ Holly Griffiths/ Katja Stout Tel: +44 (0)20 7457 2020 College Hill Life Sciences US Enquiries: Thomas Fechtner Tel: (646) 378 2900 The Trout Group LLC This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Oxford Biomedica